CUG-252
- Generic Name
- CUG-252
A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus
Phase 1
Active, not recruiting
- Conditions
- SLE (Systemic Lupus)AutoimmuneSystemic Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Cugene Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05866861
- Locations
- 🇺🇸
Site 1001, Anniston, Alabama, United States
🇺🇸Site 1011, La Jolla, California, United States
🇺🇸Site 1002, Clearwater, Florida, United States
A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Cugene Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05328557
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc., Overland Park, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath